Related Experiment Video
Updated: Jan 17, 2026
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Exploring the Relationships between Targeted Structures and Antitumor Activities of Nuclear-Targeted
Ruihan Li1, Xuan Yin1, Chuanke Chong1
1School of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, Shandong, China.
Abstract:
Polypeptides as drug delivery vehicles can achieve the targeted therapeutic effects of first-line platinum drugs in clinical practice, providing an important method to solve problems such as the high systemic toxicity of first-line platinum drugs. In this work, we employ a rational molecular conjugation strategy to design and synthesize two platinum(IV) prodrugs. The first, s-CisPt(IV)-TAT, is linked to a single nuclear-targeting polypeptide, while the second, d-CisPt(IV)-TAT, is conjugated with two of these polypeptides. Interestingly, despite the higher degree of functionalization, disubstituted d-CisPt(IV)-TAT exhibits lower reactivity and cytotoxicity than its monosubstituted counterpart. This counterintuitive result suggests that overloading with multiple ligands may reduce cellular uptake, thereby compromising therapeutic efficacy. Furthermore, both constructs are shown to induce apoptosis via DNA damage pathways, confirming their mechanism of action. These results underscore the importance of precisely tuning the ligand density in drug carriers. Our work provides valuable insights into the structure-activity relationships governing platinum prodrugs and highlights the need for a balance between functional density and biological performance in the design of next-generation polypeptide-conjugated chemotherapeutics.
Insights
Designing polypeptide-drug conjugates for platinum-based chemotherapy revealed that higher ligand density on platinum(IV) prodrugs, like d-CisPt(IV)-TAT, can paradoxically decrease efficacy due to reduced cellular uptake, emphasizing the need for balanced design.
Area of Science:
- Bioconjugation Chemistry
- Drug Delivery Systems
- Cancer Therapeutics
Background:
- Platinum-based drugs are crucial in cancer treatment but suffer from high systemic toxicity.
- Polypeptides offer a promising strategy for targeted drug delivery, mitigating side effects.
- Developing novel platinum(IV) prodrugs conjugated with polypeptides is key to improving therapeutic outcomes.
Purpose of the Study:
- To design and synthesize two platinum(IV) prodrugs conjugated with a nuclear-targeting polypeptide.
- To investigate the impact of varying polypeptide ligand density on prodrug reactivity, cellular uptake, and cytotoxicity.
- To elucidate the mechanism of action and structure-activity relationships of these novel chemotherapeutic agents.
Main Methods:
- Rational molecular conjugation strategy to synthesize s-CisPt(IV)-TAT (monosubstituted) and d-CisPt(IV)-TAT (disubstituted) platinum(IV) prodrugs.
- In vitro assays to evaluate reactivity, cytotoxicity, and cellular uptake of the synthesized prodrugs.
- Apoptosis assays to confirm the mechanism of action via DNA damage pathways.
Main Results:
- Disubstituted d-CisPt(IV)-TAT showed lower reactivity and cytotoxicity compared to monosubstituted s-CisPt(IV)-TAT, despite higher functionalization.
- This counterintuitive finding suggests that excessive ligand conjugation may impede cellular uptake, reducing therapeutic efficacy.
- Both platinum(IV) prodrug constructs successfully induced apoptosis through DNA damage pathways.
Conclusions:
- Precise tuning of ligand density is critical for optimizing the performance of polypeptide-drug conjugates.
- Structure-activity relationships indicate a balance between functional density and biological performance is necessary for effective next-generation chemotherapeutics.
- This study provides valuable insights for designing advanced polypeptide-conjugated platinum prodrugs with improved safety and efficacy profiles.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:24Tissue-Drug Binding: Localization of Drugs and its Significance
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...